ANALYSIS OF VARIANT ALLELE FREQUENCY OF JAK2V617F IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH EITHER RUXOLITINIB OR BEST AVAILABLE THERAPY IN THE RANDOMIZED PHASE 2B RUXOBEAT CLINICAL TRIAL

Authors
Category Primary study
Conference31st Congress of the European Hematology Association Congress, EHA 2026
Year 2026
This article has no abstract
Epistemonikos ID: 65da375fdc4ab6acda41aabcc049cae6e2d8c173
First added on: Aug 08, 2026